Leukemia Clinical Trials in New York State

Showing 701-708 of 708 trials

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

NCT00066885

This Phase 1/2 clinical trial is a multi-center, open-label study with three main objectives. The first (Phase 1A) is to determine the maximum-tolerated dose of DN-101 when administered in combination with Taxotere (docetaxel) every three weeks (closed). The second is to determine the maximum-tolerated dose of DN-101 when administered weekly in combination with Taxotere(docetaxel)devery three weeks (open). The third is to evaluate the safety and objective tumor response rate of the combination in NSCLC. DN-101 doses will be escalated at three dosing levels. Patients will receive oral DN-101 on day one, followed by intravenous docetaxel on day two of a 21-day cycle. Treatment cycles will be repeated at the same dose level each 21 days until disease progression or unacceptable toxicity.

Carcinoma, Non-Small-Cell Lung

Novacea80 participantsStarted Jun 2003

Berkeley, California, United States • Vallejo, California, United States • Denver, Colorado, United States +8 more locations

UNKNOWNPHASE492 miles

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

NCT00131313

This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.

Chronic Lymphocytic Leukemia

East Valley Hematology and Oncology Medical Group180 participantsStarted Jan 2003

Muscle Shoals, Alabama, United States • Burbank, California, United States • Concord, California, United States +49 more locations

Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Leukemia Trials in Other Cities

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

CP-481,715 Nickel Allergy Study.

Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer

Amonafide in Combination With Cytarabine in Secondary AML

Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia

Other Conditions in New York State